Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Reuters

Tue, August 4, 2026 astatine 5:58 AM CDT 1 min read

Aug 4 (Reuters) - Pfizer connected Tuesday somewhat raised the little extremity of ‌its full-year gross forecast aft ‌beating Wall Street estimates for second-quarter profit, driven ​by beardown request for humor thinner Eliquis.

Shares roseate 1.8% to $25.5 successful premarket trading.

Pfizer is banking connected newer medicines to offset ‌fading COVID gross ⁠and trim reliance connected aging blockbuster drugs, portion investors look ⁠for signs that its $10 cardinal acquisition of Metsera tin assistance found a meaningful ​presence successful ​the fast-growing ​obesity market.

The drugmaker, whose ‌shares person fallen much than 50% from their pandemic-era peak, expects to instrumentality to stronger maturation aft 2028.

The U.S. drugmaker present expects yearly income of $60.5 ‌billion to $62.5 billion, up ​from $59.5 cardinal to $62.5 cardinal ​forecast previously.

On ​an adjusted basis, the institution ‌reported a nett of ​77 cents ​per share, compared with analysts' estimates of 68 cents per share, according ​to information ‌compiled by LSEG.

(Reporting by Mariam Sunny ​and Mrinalika Roy successful Bengaluru; Editing ​by Anil D'Silva)